Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

Similar articles for PubMed (Select 23869073)

1.

Trick to treat: tricking the thymus to treat cancer.

Bonini C, Mondino A.

Blood. 2013 Jul 18;122(3):304-6. doi: 10.1182/blood-2013-06-504100.

2.

Immunology: Tolerance lies in the timing.

Gascoigne NR.

Nature. 2014 Nov 27;515(7528):502-3. doi: 10.1038/515502a. No abstract available.

PMID:
25428497
3.

Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection.

Schmitt TM, Aggen DH, Stromnes IM, Dossett ML, Richman SA, Kranz DM, Greenberg PD.

Blood. 2013 Jul 18;122(3):348-56. doi: 10.1182/blood-2013-01-478164. Epub 2013 May 14.

4.

Improving the efficacy and safety of engineered T cell therapy for cancer.

Shi H, Liu L, Wang Z.

Cancer Lett. 2013 Jan 28;328(2):191-7. doi: 10.1016/j.canlet.2012.09.015. Epub 2012 Sep 27. Review.

PMID:
23022475
5.

Autoreactive T cells bypass negative selection and respond to self-antigen stimulation during infection.

Enouz S, Carrié L, Merkler D, Bevan MJ, Zehn D.

J Exp Med. 2012 Sep 24;209(10):1769-79. Epub 2012 Sep 17.

6.

A broad range of self-reactivity drives thymic regulatory T cell selection to limit responses to self.

Lee HM, Bautista JL, Scott-Browne J, Mohan JF, Hsieh CS.

Immunity. 2012 Sep 21;37(3):475-86. doi: 10.1016/j.immuni.2012.07.009. Epub 2012 Aug 23.

7.

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.

Sommermeyer D, Conrad H, Krönig H, Gelfort H, Bernhard H, Uckert W.

Int J Cancer. 2013 Mar 15;132(6):1360-7. doi: 10.1002/ijc.27792. Epub 2012 Sep 14.

8.

When transgenes shape immunity: cancer immune-gene therapy.

Bonini C, Parmiani G.

J Gene Med. 2012 Jun;14(6):384-5. doi: 10.1002/jgm.2645. No abstract available.

PMID:
22736622
9.

Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility?

Jotereau F, Gervois N, Labarrière N.

Target Oncol. 2012 Mar;7(1):3-14. doi: 10.1007/s11523-012-0207-z. Epub 2012 Feb 15. Review.

PMID:
22350487
10.

Selection of regulatory T cells in the thymus.

Hsieh CS, Lee HM, Lio CW.

Nat Rev Immunol. 2012 Feb 10;12(3):157-67. doi: 10.1038/nri3155. Review.

PMID:
22322317
11.

Differential processing of self-antigens by subsets of thymic stromal cells.

Guerder S, Viret C, Luche H, Ardouin L, Malissen B.

Curr Opin Immunol. 2012 Feb;24(1):99-104. doi: 10.1016/j.coi.2012.01.008. Epub 2012 Jan 30. Review.

PMID:
22296716
12.

Thymic and peripheral differentiation of regulatory T cells.

Lee HM, Bautista JL, Hsieh CS.

Adv Immunol. 2011;112:25-71. doi: 10.1016/B978-0-12-387827-4.00002-4. Review.

PMID:
22118406
13.

T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.

Shirakura Y, Mizuno Y, Wang L, Imai N, Amaike C, Sato E, Ito M, Nukaya I, Mineno J, Takesako K, Ikeda H, Shiku H.

Cancer Sci. 2012 Jan;103(1):17-25. doi: 10.1111/j.1349-7006.2011.02111.x. Epub 2011 Nov 8.

PMID:
21951605
14.

Quantitative impact of thymic selection on Foxp3+ and Foxp3- subsets of self-peptide/MHC class II-specific CD4+ T cells.

Moon JJ, Dash P, Oguin TH 3rd, McClaren JL, Chu HH, Thomas PG, Jenkins MK.

Proc Natl Acad Sci U S A. 2011 Aug 30;108(35):14602-7. doi: 10.1073/pnas.1109806108. Epub 2011 Aug 22.

15.

Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia.

Ochi T, Fujiwara H, Yasukawa M.

J Biomed Biotechnol. 2010;2010:521248. doi: 10.1155/2010/521248. Epub 2010 May 5. Review.

16.

MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.

Chhabra A.

Endocr Metab Immune Disord Drug Targets. 2009 Dec;9(4):344-52.

PMID:
19807670
17.

T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.

Circosta P, Granziero L, Follenzi A, Vigna E, Stella S, Vallario A, Elia AR, Gammaitoni L, Vitaggio K, Orso F, Geuna M, Sangiolo D, Todorovic M, Giachino C, Cignetti A.

Hum Gene Ther. 2009 Dec;20(12):1576-88. doi: 10.1089/hum.2009.117.

PMID:
19678763
18.

Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity.

Wilde S, Sommermeyer D, Frankenberger B, Schiemann M, Milosevic S, Spranger S, Pohla H, Uckert W, Busch DH, Schendel DJ.

Blood. 2009 Sep 3;114(10):2131-9. doi: 10.1182/blood-2009-03-209387. Epub 2009 Jul 8.

19.

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA.

Blood. 2009 Jul 16;114(3):535-46. doi: 10.1182/blood-2009-03-211714. Epub 2009 May 18.

20.

Affinity threshold for thymic selection through a T-cell receptor-co-receptor zipper.

Palmer E, Naeher D.

Nat Rev Immunol. 2009 Mar;9(3):207-13. doi: 10.1038/nri2469.

PMID:
19151748
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk